title: The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
abstract: Intervention studies have shown that angiotensin receptor blocker therapy may reduce the incidence of type 2 diabetes mellitus. It is unknown whether short-term angiotensin receptor blocker therapy can improve glucose and lipid metabolism in insulin-resistant subjects. We evaluated the effect of telmisartan (40 mg/d, 12 weeks) in 20 subjects with insulin resistance (body mass index, 31.8 +/- 3.31 kg/m(2); triglycerides, 179 +/- 98 mg/dL; glucose, 104 +/- 9 mg/dL; homeostasis model assessment index, 3.78 +/- 1.52) in a randomized, placebo-controlled, double-blind, cross-over study. At the end of each treatment phase, oral and intravenous glucose tolerance tests including C-peptide and insulin measurements were performed, and fasting and postprandial lipids were determined. Compared to placebo, telmisartan resulted in a reduction in homeostasis model assessment index (-11%, P = .06) and glucose area under the curve during intravenous glucose tolerance (-11%, P = .04). We observed an increase (+32%, P = .05) in the insulinogenic index indicating an improved beta-cell function. Fasting and postprandial lipid parameters did not change. We observed an increase in adiponectin (6%, P = .09), whereas IL-6, high-sensitivity C-reactive protein, fibrinogen, and free fatty acid concentrations did not change. This indicates that the improvement in glucose metabolism is rather mediated by direct effects, such as activation of PPARgamma. Our data indicate that in insulin-resistant persons 12 weeks of telmisartan result in a significant improvement in glucose metabolism with a predominant improvement in beta-cell function.
authors.affiliation: Medizinische Klinik und Poliklinik II, Klinikum Grosshadern, Ludwig-Maximilians-Universität, 81377 Munich, Germany.
authors.forename: Jutta M
authors.initials: JM
authors.lastname: Nagel
authors.forename: Anne B
authors.initials: AB
authors.lastname: Tietz
authors.forename: Burkhard
authors.initials: B
authors.lastname: Göke
authors.forename: Klaus G
authors.initials: KG
authors.lastname: Parhofer
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects*; D002096:C-Peptide / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005951:Glucose Tolerance Test; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D050177:Overweight; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D052242:Adiponectin; D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001565:Benzoates; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D008055:Lipids; D000077333:Telmisartan